AstraZeneca to invest $50 billion in u.s. to boost drug manufacturing and R&D by 2030

By The Inspirer.

Global biopharmaceutical giant AstraZeneca has announced plans to invest $50 billion in the United States by 2030, marking a historic commitment to strengthening domestic drug manufacturing and research and development.

The investment aims to support the company’s goal of reaching $80 billion in global revenue by the end of the decade, with half of that revenue expected to come from the U.S. market.

A proposed multi-billion-dollar manufacturing hub in the Commonwealth of Virginia will serve as the cornerstone of the initiative. It will be the largest single facility investment in AstraZeneca’s history.

The site will focus on producing drug substances for the company’s expanding portfolio targeting chronic diseases such as obesity, cardiovascular conditions, and metabolic disorders. Medicines planned for production include oral GLP-1, baxdrostat, oral PCSK9, and other next-generation combination therapies.

“AstraZeneca’s commitment to American innovation and patient access is stronger than ever,” said Pascal Soriot, Chief Executive Officer of AstraZeneca. “This investment reflects our confidence in the U.S. as a global leader in biopharmaceuticals and strengthens our mission to deliver cutting-edge medicines to patients worldwide.”

The Virginia-based facility will use AI-driven automation and advanced data analytics to optimize drug production. It will manufacture small molecules, peptides, and oligonucleotides—key components in AstraZeneca’s pipeline of treatments for chronic and lifestyle-related diseases.

Virginia Governor Glenn Youngkin welcomed the investment, calling it a transformative project that will create hundreds of highly skilled jobs, strengthen the nation’s domestic supply chain, and enhance Virginia’s standing in advanced manufacturing.

The federal government also praised the move. U.S. Secretary of Commerce Howard Lutnick described it as a “historic” turning point in reducing reliance on foreign pharmaceutical supply chains.

“For decades Americans have been dependent on imports for critical medicines,” Lutnick said. “This announcement signals a major shift, bringing thousands of jobs and billions of dollars back into the U.S. economy.”

The $50 billion investment will span multiple states and facilities. It includes the expansion of AstraZeneca’s R&D facility in Gaithersburg, Maryland; a new research center in Kendall Square, Cambridge, Massachusetts; manufacturing facilities for cell therapy in Rockville, Maryland, and Tarzana, California; expanded continuous manufacturing in Mount Vernon, Indiana; and specialty production growth in Coppell, Texas. New sites will also be established to support clinical trial supply chains.

The initiative is expected to generate tens of thousands of direct and indirect jobs, many in high-tech and biopharmaceutical sectors.

The U.S. remains AstraZeneca’s largest market, currently generating 42% of its total revenue, with a goal to reach 50% by 2030.

The company operates 19 sites across the country and employs over 18,000 people, contributing $5 billion directly to the U.S. economy in 2024.

About AstraZeneca

Headquartered in Cambridge, UK, AstraZeneca is a science-led global biopharmaceutical company focusing on Oncology, Rare Diseases, and BioPharmaceuticals including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its products are used in over 125 countries, serving millions of patients worldwide.